Zoetis/$ZTS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Ticker
$ZTS
Sector
Primary listing
NYSE
Employees
13,800
Headquarters
Website
Zoetis Metrics
BasicAdvanced
$53B
20.25
$5.94
0.96
$1.93
1.66%
Price and volume
Market cap
$53B
Beta
0.96
52-week high
$177.40
52-week low
$117.26
Average daily volume
3.6M
Dividend rate
$1.93
Financial strength
Current ratio
3.643
Quick ratio
2.006
Long term debt to equity
135.05
Total debt to equity
135.05
Dividend payout ratio (TTM)
32.55%
Interest coverage (TTM)
16.50%
Profitability
EBITDA (TTM)
3,991
Gross margin (TTM)
71.74%
Net profit margin (TTM)
28.21%
Operating margin (TTM)
37.88%
Effective tax rate (TTM)
20.41%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
15.08%
Return on equity (TTM)
49.87%
Valuation
Price to earnings (TTM)
20.254
Price to revenue (TTM)
5.714
Price to book
9.83
Price to tangible book (TTM)
33.3
Price to free cash flow (TTM)
23.97
Free cash flow yield (TTM)
4.17%
Free cash flow per share (TTM)
5.016
Dividend yield (TTM)
1.61%
Forward dividend yield
1.66%
Growth
Revenue change (TTM)
2.68%
Earnings per share change (TTM)
11.64%
3-year revenue growth (CAGR)
5.48%
10-year revenue growth (CAGR)
6.92%
3-year earnings per share growth (CAGR)
10.69%
10-year earnings per share growth (CAGR)
21.03%
3-year dividend per share growth (CAGR)
16.40%
10-year dividend per share growth (CAGR)
19.66%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Bulls say / Bears say
Zoetis’ Q2 companion animal segment revenue climbed 8% year-over-year to $1.79 billion, driven by strong demand for its Simparica Trio flea, tick and heartworm treatment and key dermatology products (Reuters).
Overall Q2 revenue rose 4% to $2.46 billion, and adjusted EPS of $1.76 beat the $1.62 consensus, underscoring Zoetis’ ability to exceed expectations and capture underlying demand momentum (Reuters).
Following Q2 outperformance, Zoetis raised its full-year 2025 revenue guidance to $9.45 billion–$9.60 billion and its adjusted EPS guidance to $6.30–$6.40, signaling confidence in its growth outlook (Reuters).
Zoetis trimmed its full-year 2025 revenue forecast to $9.40 billion–$9.48 billion—below analysts’ $9.52 billion consensus—citing softer demand and causing shares to fall over 8% in premarket trading (Reuters).
Distributor hesitancy and tighter consumer spending led to muted demand for pet medicines and vaccines in Q3, with the companion animal segment growing just 3%, underscoring consumer vulnerability in its core pet care business (Reuters).
Third-quarter revenue rose only 1% to $2.40 billion—missing the $2.41 billion consensus—highlighting volume weakness amid a 4% drop in livestock product sales and signaling broader operational challenges (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Zoetis News
AllArticlesVideos
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Benzinga4 days ago
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
Business Wire5 days ago
Buy Zoetis Stock Today?
Forbes1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Zoetis stock?
Zoetis (ZTS) has a market cap of $53B as of November 08, 2025.
What is the P/E ratio for Zoetis stock?
The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 20.25 as of November 08, 2025.
Does Zoetis stock pay dividends?
Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of November 08, 2025, the dividend rate is $1.932 and the yield is 1.66%. Zoetis has a payout ratio of 32.55% on a trailing twelve-month basis.
When is the next Zoetis dividend payment date?
The next Zoetis (ZTS) dividend payment is scheduled for December 02, 2025.
What is the beta indicator for Zoetis?
Zoetis (ZTS) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.